Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan

Naohiro Sekiguchi, Junko Nishimoto, Kazuki Tanimoto, Shigeru Kusumoto, Yasushi Onishi, Takashi Watanabe, Yukio Kobayashi, Hisao Asamura, Yoshikazu Kagami, Yoshihiro Matsuno, Kensei Tobinai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Several clinicopathologic studies of primary mediastinal large B-cell lymphoma (Med-DLBCL) have been reported from Western countries; however, only a few series of at most 10 cases are available in Japan. To further clarify the Med-DLBCL occurring in Japan, we analyzed the clinical features of 28 patients with Med-DLBCL diagnoses who were treated at the National Cancer Center Hospital between 1982 and 2002. The median age was 37 years (range, 18-80 years). The ages of 16 male patients ranged widely from 18 to 80 years, whereas the 12 female patients appeared to show a single age peak at 20 to 40 years. Only 13 patients (46%) achieved a complete response with initial treatments, mostly by CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisolone) followed by radiotherapy. The estimated 3-year overall and failure-free survival rates were 32% and 33%, respectively, indicating the relatively unfavorable prognosis of the patients in our series. The following factors were found to be significantly associated with shortened survival prospects: age >60 years, serum lactate dehydrogenase level greater than normal, performance status >1, and presence of bulky mediastinal mass. In conclusion, the clinical features of Japanese patients with Med-DLBCL may be different from those with the disease in Western countries. Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalInternational Journal of Hematology
Volume79
Issue number5
DOIs
Publication statusPublished - 2004 Jun
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Japan
Vincristine
Cancer Care Facilities
Prednisolone
Clinical Studies
L-Lactate Dehydrogenase
Doxorubicin
Cyclophosphamide
Multicenter Studies
Radiotherapy
Survival Rate
Survival
Serum

Keywords

  • Geographical variation
  • Japan
  • Primary mediastinal large B-cell lymphoma
  • Prognostic factor
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Sekiguchi, N., Nishimoto, J., Tanimoto, K., Kusumoto, S., Onishi, Y., Watanabe, T., ... Tobinai, K. (2004). Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan. International Journal of Hematology, 79(5), 465-471. https://doi.org/10.1532/IJH97.03173

Primary mediastinal large B-cell lymphoma : A single-institution clinical study in Japan. / Sekiguchi, Naohiro; Nishimoto, Junko; Tanimoto, Kazuki; Kusumoto, Shigeru; Onishi, Yasushi; Watanabe, Takashi; Kobayashi, Yukio; Asamura, Hisao; Kagami, Yoshikazu; Matsuno, Yoshihiro; Tobinai, Kensei.

In: International Journal of Hematology, Vol. 79, No. 5, 06.2004, p. 465-471.

Research output: Contribution to journalArticle

Sekiguchi, N, Nishimoto, J, Tanimoto, K, Kusumoto, S, Onishi, Y, Watanabe, T, Kobayashi, Y, Asamura, H, Kagami, Y, Matsuno, Y & Tobinai, K 2004, 'Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan', International Journal of Hematology, vol. 79, no. 5, pp. 465-471. https://doi.org/10.1532/IJH97.03173
Sekiguchi N, Nishimoto J, Tanimoto K, Kusumoto S, Onishi Y, Watanabe T et al. Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan. International Journal of Hematology. 2004 Jun;79(5):465-471. https://doi.org/10.1532/IJH97.03173
Sekiguchi, Naohiro ; Nishimoto, Junko ; Tanimoto, Kazuki ; Kusumoto, Shigeru ; Onishi, Yasushi ; Watanabe, Takashi ; Kobayashi, Yukio ; Asamura, Hisao ; Kagami, Yoshikazu ; Matsuno, Yoshihiro ; Tobinai, Kensei. / Primary mediastinal large B-cell lymphoma : A single-institution clinical study in Japan. In: International Journal of Hematology. 2004 ; Vol. 79, No. 5. pp. 465-471.
@article{8142130fcd0842f7b70e06312d0ab710,
title = "Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan",
abstract = "Several clinicopathologic studies of primary mediastinal large B-cell lymphoma (Med-DLBCL) have been reported from Western countries; however, only a few series of at most 10 cases are available in Japan. To further clarify the Med-DLBCL occurring in Japan, we analyzed the clinical features of 28 patients with Med-DLBCL diagnoses who were treated at the National Cancer Center Hospital between 1982 and 2002. The median age was 37 years (range, 18-80 years). The ages of 16 male patients ranged widely from 18 to 80 years, whereas the 12 female patients appeared to show a single age peak at 20 to 40 years. Only 13 patients (46{\%}) achieved a complete response with initial treatments, mostly by CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisolone) followed by radiotherapy. The estimated 3-year overall and failure-free survival rates were 32{\%} and 33{\%}, respectively, indicating the relatively unfavorable prognosis of the patients in our series. The following factors were found to be significantly associated with shortened survival prospects: age >60 years, serum lactate dehydrogenase level greater than normal, performance status >1, and presence of bulky mediastinal mass. In conclusion, the clinical features of Japanese patients with Med-DLBCL may be different from those with the disease in Western countries. Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed.",
keywords = "Geographical variation, Japan, Primary mediastinal large B-cell lymphoma, Prognostic factor, Treatment",
author = "Naohiro Sekiguchi and Junko Nishimoto and Kazuki Tanimoto and Shigeru Kusumoto and Yasushi Onishi and Takashi Watanabe and Yukio Kobayashi and Hisao Asamura and Yoshikazu Kagami and Yoshihiro Matsuno and Kensei Tobinai",
year = "2004",
month = "6",
doi = "10.1532/IJH97.03173",
language = "English",
volume = "79",
pages = "465--471",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Primary mediastinal large B-cell lymphoma

T2 - A single-institution clinical study in Japan

AU - Sekiguchi, Naohiro

AU - Nishimoto, Junko

AU - Tanimoto, Kazuki

AU - Kusumoto, Shigeru

AU - Onishi, Yasushi

AU - Watanabe, Takashi

AU - Kobayashi, Yukio

AU - Asamura, Hisao

AU - Kagami, Yoshikazu

AU - Matsuno, Yoshihiro

AU - Tobinai, Kensei

PY - 2004/6

Y1 - 2004/6

N2 - Several clinicopathologic studies of primary mediastinal large B-cell lymphoma (Med-DLBCL) have been reported from Western countries; however, only a few series of at most 10 cases are available in Japan. To further clarify the Med-DLBCL occurring in Japan, we analyzed the clinical features of 28 patients with Med-DLBCL diagnoses who were treated at the National Cancer Center Hospital between 1982 and 2002. The median age was 37 years (range, 18-80 years). The ages of 16 male patients ranged widely from 18 to 80 years, whereas the 12 female patients appeared to show a single age peak at 20 to 40 years. Only 13 patients (46%) achieved a complete response with initial treatments, mostly by CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisolone) followed by radiotherapy. The estimated 3-year overall and failure-free survival rates were 32% and 33%, respectively, indicating the relatively unfavorable prognosis of the patients in our series. The following factors were found to be significantly associated with shortened survival prospects: age >60 years, serum lactate dehydrogenase level greater than normal, performance status >1, and presence of bulky mediastinal mass. In conclusion, the clinical features of Japanese patients with Med-DLBCL may be different from those with the disease in Western countries. Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed.

AB - Several clinicopathologic studies of primary mediastinal large B-cell lymphoma (Med-DLBCL) have been reported from Western countries; however, only a few series of at most 10 cases are available in Japan. To further clarify the Med-DLBCL occurring in Japan, we analyzed the clinical features of 28 patients with Med-DLBCL diagnoses who were treated at the National Cancer Center Hospital between 1982 and 2002. The median age was 37 years (range, 18-80 years). The ages of 16 male patients ranged widely from 18 to 80 years, whereas the 12 female patients appeared to show a single age peak at 20 to 40 years. Only 13 patients (46%) achieved a complete response with initial treatments, mostly by CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisolone) followed by radiotherapy. The estimated 3-year overall and failure-free survival rates were 32% and 33%, respectively, indicating the relatively unfavorable prognosis of the patients in our series. The following factors were found to be significantly associated with shortened survival prospects: age >60 years, serum lactate dehydrogenase level greater than normal, performance status >1, and presence of bulky mediastinal mass. In conclusion, the clinical features of Japanese patients with Med-DLBCL may be different from those with the disease in Western countries. Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed.

KW - Geographical variation

KW - Japan

KW - Primary mediastinal large B-cell lymphoma

KW - Prognostic factor

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=3042658501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042658501&partnerID=8YFLogxK

U2 - 10.1532/IJH97.03173

DO - 10.1532/IJH97.03173

M3 - Article

C2 - 15239397

AN - SCOPUS:3042658501

VL - 79

SP - 465

EP - 471

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -